
    
      This is a multicenter, open label, single arm, phase II study. There will be no placebo usage
      within this trial. In the part I, dose escalation part, of this trial 6 patients will be
      included in each dose level. There will be 4 cohorts, administering up to a maximum of 4
      cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.

      Treatment regimen part I:

      Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day
      1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3
      Cytarabine 2x2 g/m² day 4

      ...repeat day 22, up to a maximum of 4 cycles In part I, after inclusion of 6 patients, each
      patient has to receive at least 1 complete cycle w/o dose limiting toxicity until the
      enrollment into the next cohort can be initiated.

      In the part II of the trial 40 patients will be included to receive the full target dose,
      established within the part I of the study.
    
  